DekaBank Deutsche Girozentrale Purchases 25562 Shares of Infosys Ltd (NYSE:INFY)

DekaBank Deutsche Girozentrale grew its holdings in Infosys Ltd (NYSE:INFY) by 13.7% during the 2nd quarter, according to its most recent Form 13F …

Infosys logoDekaBank Deutsche Girozentrale grew its holdings in Infosys Ltd (NYSE:INFY) by 13.7% during the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 212,099 shares of the technology company’s stock after acquiring an additional 25,562 shares during the period. DekaBank Deutsche Girozentrale’s holdings in Infosys were worth $2,253,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also made changes to their positions in the company. Pennsylvania Trust Co acquired a new position in Infosys during the 1st quarter worth $1,502,000. Butensky & Cohen Financial Security Inc. raised its position in shares of Infosys by 5.4% during the 2nd quarter. Butensky & Cohen Financial Security Inc. now owns 232,950 shares of the technology company’s stock worth $2,493,000 after buying an additional 11,915 shares in the last quarter. Nomura Asset Management Co. Ltd. raised its position in shares of Infosys by 1,019.7% during the 1st quarter. Nomura Asset Management Co. Ltd. now owns 694,200 shares of the technology company’s stock worth $7,587,000 after buying an additional 632,200 shares in the last quarter. Advisory Services Network LLC raised its position in shares of Infosys by 491.3% during the 1st quarter. Advisory Services Network LLC now owns 24,999 shares of the technology company’s stock worth $273,000 after buying an additional 20,771 shares in the last quarter. Finally, First Trust Advisors LP raised its position in shares of Infosys by 7.7% during the 2nd quarter. First Trust Advisors LP now owns 4,533,226 shares of the technology company’s stock worth $48,506,000 after buying an additional 323,228 shares in the last quarter. Institutional investors and hedge funds own 17.28% of the company’s stock.

INFY traded up $0.05 on Wednesday, reaching $11.20. 183,039 shares of the company traded hands, compared to its average volume of 10,115,486. The stock’s 50 day moving average price is $11.22 and its 200-day moving average price is $10.78. Infosys Ltd has a 52-week low of $8.85 and a 52-week high of $11.64. The company has a market cap of $47.46 billion, a price-to-earnings ratio of 20.72, a PEG ratio of 2.13 and a beta of 0.53.

Infosys (NYSE:INFY) last announced its quarterly earnings data on Friday, July 12th. The technology company reported $0.13 EPS for the quarter, meeting the Zacks’ consensus estimate of $0.13. Infosys had a net margin of 18.26% and a return on equity of 25.55%. The firm had revenue of $218.03 billion for the quarter, compared to the consensus estimate of $216.51 billion. During the same period in the previous year, the firm posted $0.13 earnings per share. The firm’s revenue was up 14.0% on a year-over-year basis. On average, sell-side analysts anticipate that Infosys Ltd will post 0.55 earnings per share for the current year.

A number of research firms have commented on INFY. Zacks Investment Research upgraded shares of Infosys from a “sell” rating to a “hold” rating in a research report on Friday, May 17th. Wells Fargo & Co set a $12.00 price objective on shares of Infosys and gave the stock a “hold” rating in a research note on Friday, May 31st. BMO Capital Markets set a $13.00 price objective on shares of Infosys and gave the stock a “hold” rating in a research note on Monday, July 15th. Wedbush reaffirmed a “neutral” rating on shares of Infosys in a research note on Friday, July 12th. Finally, Citigroup raised shares of Infosys from a “neutral” rating to a “buy” rating in a research note on Friday, July 12th. Two investment analysts have rated the stock with a sell rating, thirteen have assigned a hold rating and one has issued a buy rating to the company. The company currently has an average rating of “Hold” and an average target price of $10.96.

Infosys Profile

Infosys Limited, together with its subsidiaries, provides consulting, technology, and outsourcing services in North America, Europe, India, and internationally. It provides business information technology services, including application development and maintenance, independent validation, infrastructure management, and business process management services, as well as engineering services, such as engineering and life cycle solutions; and consulting and systems integration services comprising consulting, enterprise solutions, systems integration, and advanced technologies.

Read More: What is Green Investing?

Institutional Ownership by Quarter for Infosys (NYSE:INFY)

Receive News & Ratings for Infosys Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Infosys and related companies with MarketBeat.com’s FREE daily email newsletter.

Related Posts:

  • No Related Posts

Interactive Brokers Group (NASDAQ:CBOE) Given $116.44 Average Target Price by Brokerages

Shares of Interactive Brokers Group (NASDAQ:CBOE) have earned an … Cboe Global Markets, Inc, through its subsidiaries, operates as an options …

Interactive Brokers Group logoShares of Interactive Brokers Group (NASDAQ:CBOE) have earned an average broker rating score of 1.89 (Buy) from the nine brokers that cover the company, Zacks Investment Research reports. Four investment analysts have rated the stock with a hold rating and five have given a strong buy rating to the company. Interactive Brokers Group’s rating score has declined by 3.8% in the last 90 days as a result of a number of analysts’ ratings changes.

Analysts have set a 12-month consensus price objective of $116.44 for the company and are anticipating that the company will post $1.10 earnings per share for the current quarter, according to Zacks. Zacks has also assigned Interactive Brokers Group an industry rank of 176 out of 256 based on the ratings given to related companies.

Separately, Barclays boosted their price objective on shares of Interactive Brokers Group from $102.00 to $106.00 and gave the company an “equal weight” rating in a research note on Monday, August 5th.

In other Interactive Brokers Group news, COO Christopher A. Isaacson sold 10,000 shares of the business’s stock in a transaction that occurred on Thursday, August 15th. The shares were sold at an average price of $121.19, for a total value of $1,211,900.00. Following the completion of the transaction, the chief operating officer now owns 74,644 shares of the company’s stock, valued at approximately $9,046,106.36. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, Director Michael L. Richter sold 2,600 shares of the business’s stock in a transaction that occurred on Thursday, August 15th. The stock was sold at an average price of $120.50, for a total transaction of $313,300.00. Following the completion of the transaction, the director now directly owns 21,925 shares of the company’s stock, valued at approximately $2,641,962.50. The disclosure for this sale can be found here. In the last three months, insiders sold 24,007 shares of company stock valued at $2,850,741.

NASDAQ CBOE opened at $120.06 on Friday. Interactive Brokers Group has a 12-month low of $87.87 and a 12-month high of $122.88.

Interactive Brokers Group (NASDAQ:CBOE) last posted its quarterly earnings results on Friday, August 2nd. The company reported $1.13 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.07 by $0.06. The business had revenue of $283.20 million during the quarter, compared to the consensus estimate of $282.40 million. The business’s revenue for the quarter was down .1% on a year-over-year basis. During the same period last year, the firm earned $1.05 EPS.

The company also recently disclosed a dividend, which will be paid on Friday, September 13th. Investors of record on Friday, August 30th will be paid a dividend of $0.36 per share. The ex-dividend date is Thursday, August 29th.

About Interactive Brokers Group

Cboe Global Markets, Inc, through its subsidiaries, operates as an options exchange in the United States. It operates in five segments: Options, U.S. Equities, Futures, European Equities, and Global FX. The Options segment trades in listed market indexes. The U.S. Equities segment trades in listed cash equities; and offers exchange-traded products (ETP) transaction and ETP listing services.

Read More: How is the Producer Price Index calculated?

Get a free copy of the Zacks research report on Interactive Brokers Group (CBOE)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Interactive Brokers Group Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Interactive Brokers Group and related companies with MarketBeat.com’s FREE daily email newsletter.

Related Posts:

  • No Related Posts

Honkamp Krueger Financial Services Inc. Increases Holdings in Aurora Cannabis Inc (NYSE:ACB)

Honkamp Krueger Financial Services Inc. grew its holdings in shares of Aurora Cannabis Inc (NYSE:ACB) by 128.6% during the 2nd quarter, Holdings …

Aurora Cannabis logoHonkamp Krueger Financial Services Inc. grew its holdings in shares of Aurora Cannabis Inc (NYSE:ACB) by 128.6% during the 2nd quarter, Holdings Channel reports. The institutional investor owned 23,041 shares of the company’s stock after acquiring an additional 12,964 shares during the quarter. Honkamp Krueger Financial Services Inc.’s holdings in Aurora Cannabis were worth $171,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also made changes to their positions in ACB. Deutsche Bank AG bought a new position in Aurora Cannabis during the 4th quarter valued at about $3,105,000. Swiss National Bank grew its holdings in Aurora Cannabis by 5.9% during the 1st quarter. Swiss National Bank now owns 2,443,965 shares of the company’s stock valued at $22,117,000 after purchasing an additional 136,300 shares during the last quarter. Janus Henderson Group PLC grew its holdings in Aurora Cannabis by 98.2% during the 2nd quarter. Janus Henderson Group PLC now owns 727,520 shares of the company’s stock valued at $5,711,000 after purchasing an additional 360,390 shares during the last quarter. Private Advisor Group LLC grew its holdings in Aurora Cannabis by 33.1% during the 1st quarter. Private Advisor Group LLC now owns 147,763 shares of the company’s stock valued at $1,339,000 after purchasing an additional 36,765 shares during the last quarter. Finally, North Star Investment Management Corp. grew its holdings in Aurora Cannabis by 22.4% during the 2nd quarter. North Star Investment Management Corp. now owns 17,500 shares of the company’s stock valued at $137,000 after purchasing an additional 3,200 shares during the last quarter. Hedge funds and other institutional investors own 9.11% of the company’s stock.

Shares of ACB stock opened at $5.80 on Tuesday. The company has a debt-to-equity ratio of 0.10, a current ratio of 2.37 and a quick ratio of 1.98. The company has a market capitalization of $5.74 billion, a P/E ratio of 56.40 and a beta of 2.44. The company’s 50-day simple moving average is $6.46 and its two-hundred day simple moving average is $7.78. Aurora Cannabis Inc has a one year low of $4.58 and a one year high of $12.52.

Several equities analysts recently commented on ACB shares. Piper Jaffray Companies started coverage on shares of Aurora Cannabis in a report on Monday, August 12th. They set a “neutral” rating and a $7.00 price target on the stock. Bank of America downgraded shares of Aurora Cannabis from a “buy” rating to a “neutral” rating and set a $7.30 price target on the stock. in a report on Thursday, July 18th. Zacks Investment Research downgraded shares of Aurora Cannabis from a “buy” rating to a “sell” rating in a report on Thursday, August 15th. Stifel Nicolaus started coverage on shares of Aurora Cannabis in a report on Wednesday, June 5th. They set a “hold” rating on the stock. Finally, LADENBURG THALM/SH SH started coverage on shares of Aurora Cannabis in a report on Wednesday, July 17th. They set a “buy” rating and a $9.00 price target on the stock. One research analyst has rated the stock with a sell rating, five have assigned a hold rating and six have issued a buy rating to the stock. The company presently has an average rating of “Hold” and a consensus target price of $8.23.

Aurora Cannabis Company Profile

Aurora Cannabis Inc produces and distributes medical cannabis products. It is vertically integrated and horizontally diversified across various segments of the cannabis value chain, from facility engineering and design to cannabis breeding, genetics research, production, derivatives, high value-add product development, home cultivation, wholesale, and retail distribution.

See Also: What is the 52-week high/low?

Want to see what other hedge funds are holding ACB?Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Aurora Cannabis Inc (NYSE:ACB).

Institutional Ownership by Quarter for Aurora Cannabis (NYSE:ACB)

Receive News & Ratings for Aurora Cannabis Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Aurora Cannabis and related companies with MarketBeat.com’s FREE daily email newsletter.

Related Posts:

  • No Related Posts

TrovaGene (NASDAQ:TROV) Given a $6.00 Price Target at Maxim Group

Renaissance Technologies LLC boosted its position in TrovaGene by 55.5% during the second quarter. Renaissance Technologies LLC now owns …

TrovaGene Inc logoMaxim Group set a $6.00 target price on TrovaGene (NASDAQ:TROV) in a research report released on Wednesday, July 31st, TipRanks reports. The brokerage currently has a buy rating on the medical research company’s stock.

A number of other equities research analysts have also recently commented on TROV. ValuEngine upgraded shares of TrovaGene from a hold rating to a buy rating in a report on Tuesday, July 2nd. Zacks Investment Research downgraded shares of TrovaGene from a buy rating to a hold rating in a research report on Thursday, May 9th. Finally, Noble Financial set a $23.00 price objective on shares of TrovaGene and gave the company a buy rating in a research report on Friday, May 24th.

TROV stock traded down $0.30 during trading on Wednesday, reaching $1.94. The company had a trading volume of 995,200 shares, compared to its average volume of 578,692. The company has a market cap of $12.90 million, a P/E ratio of -0.23 and a beta of 0.74. The company has a debt-to-equity ratio of 0.15, a current ratio of 3.20 and a quick ratio of 3.20. TrovaGene has a 52 week low of $1.30 and a 52 week high of $9.65. The business has a 50 day moving average of $2.01 and a 200 day moving average of $2.77.

TrovaGene (NASDAQ:TROV) last announced its quarterly earnings data on Thursday, August 8th. The medical research company reported ($0.79) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.52) by ($0.27). TrovaGene had a negative return on equity of 149.88% and a negative net margin of 3,424.46%. The business had revenue of $0.14 million during the quarter. Research analysts expect that TrovaGene will post -4.02 earnings per share for the current year.

Several large investors have recently modified their holdings of the business. Morgan Stanley grew its position in TrovaGene by 26,190.3% in the second quarter. Morgan Stanley now owns 27,079 shares of the medical research company’s stock worth $68,000 after acquiring an additional 26,976 shares in the last quarter. Vanguard Group Inc. boosted its position in TrovaGene by 320.8% during the second quarter. Vanguard Group Inc. now owns 285,150 shares of the medical research company’s stock valued at $713,000 after buying an additional 217,386 shares during the period. Renaissance Technologies LLC boosted its position in TrovaGene by 55.5% during the second quarter. Renaissance Technologies LLC now owns 249,121 shares of the medical research company’s stock valued at $623,000 after buying an additional 88,900 shares during the period. Finally, Wedbush Securities Inc. bought a new position in shares of TrovaGene during the second quarter valued at about $25,000. 7.24% of the stock is owned by institutional investors and hedge funds.

TrovaGene Company Profile

Trovagene, Inc, a clinical-stage, precision medicine oncology therapeutics company, develops oncology therapeutics for cancer care by leveraging its proprietary Precision Cancer Monitoring (PCM) technology in tumor genomics. Its lead drug candidate, PCM-075, is a Polo-like Kinase 1 selective adenosine triphosphate competitive inhibitor.

Featured Article: What economic reports are most valuable to investors?

Receive News & Ratings for TrovaGene Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for TrovaGene and related companies with MarketBeat.com’s FREE daily email newsletter.

Related Posts:

  • No Related Posts

CrowdStrike Holdings (CRWD) Gains But Lags Market: What You Should Know

In the latest trading session, CrowdStrike Holdings (CRWD) closed at $88.88, marking a +0.51% move from the previous day. This change lagged the …

In the latest trading session, CrowdStrike Holdings (CRWD) closed at $88.88, marking a +0.51% move from the previous day. This change lagged the S&P 500’s 1.1% gain on the day. Meanwhile, the Dow gained 1.05%, and the Nasdaq, a tech-heavy index, added 1.32%.

Heading into today, shares of the cloud-based security company had lost 4.17% over the past month, outpacing the Computer and Technology sector’s loss of 5.47% and the S&P 500’s loss of 5.05% in that time.

CRWD will be looking to display strength as it nears its next earnings release, which is expected to be September 5, 2019.

Any recent changes to analyst estimates for CRWD should also be noted by investors. Recent revisions tend to reflect the latest near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the company’s business outlook.

Based on our research, we believe these estimate revisions are directly related to near-team stock moves. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.

Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the past month, the Zacks Consensus EPS estimate remained stagnant. CRWD is holding a Zacks Rank of #3 (Hold) right now.

The Internet – Software industry is part of the Computer and Technology sector. This industry currently has a Zacks Industry Rank of 98, which puts it in the top 39% of all 250+ industries.

The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

Make sure to utilize Zacks. Com to follow all of these stock-moving metrics, and more, in the coming trading sessions.


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

CrowdStrike Holdings Inc. (CRWD) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

Related Posts:

  • No Related Posts